CABOSEQ 3-Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Saved in:
| Title: | CABOSEQ 3-Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). |
|---|---|
| Authors: | Lemelin A; Arthur JE Child Comprehensive Cancer Centre, University of Calgary, Calgary, Canada., Maj D; Arthur JE Child Comprehensive Cancer Centre, University of Calgary, Calgary, Canada. Electronic address: David.Maj@AlbertaHealthServices.ca., Takemura K; Department of Genitourinary Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Boyne DJ; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada., Warkentin MT; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada., Brenner DR; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada., Cheung WY; Arthur JE Child Comprehensive Cancer Centre, University of Calgary, Calgary, Canada; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada., Wells C; Arthur JE Child Comprehensive Cancer Centre, University of Calgary, Calgary, Canada., Labaki C; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., McGregor BA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Contreras LM; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, USA., Pal SK; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, USA., Beuselinck B; Department of General Medical Oncology and Laboratory for Experimental Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium., McKay RR; Department of Oncology, Moores Cancer Center, University of California San Diego, La Jolla, USA., Szabados B; Barts Cancer Institute, Queen Mary University of London, London, UK., Powles T; Barts Cancer Institute, Queen Mary University of London, London, UK., Yuasa T; Department of Genitourinary Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan., Ludwig L; Ipsen Biopharmaceuticals Canada, Inc., Mississauga, Canada., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA., Heng DYC; Arthur JE Child Comprehensive Cancer Centre, University of Calgary, Calgary, Canada. |
| Source: | Clinical genitourinary cancer [Clin Genitourin Cancer] 2025 Dec; Vol. 23 (6), pp. 102431. Date of Electronic Publication: 2025 Sep 09. |
| Publication Type: | Journal Article; Comparative Study |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41086537 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: CABOSEQ 3-Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Lemelin+A%22">Lemelin A</searchLink>; Arthur JE Child Comprehensive Cancer Centre, University of Calgary, Calgary, Canada.<br /><searchLink fieldCode="AU" term="%22Maj+D%22">Maj D</searchLink>; Arthur JE Child Comprehensive Cancer Centre, University of Calgary, Calgary, Canada. Electronic address: David.Maj@AlbertaHealthServices.ca.<br /><searchLink fieldCode="AU" term="%22Takemura+K%22">Takemura K</searchLink>; Department of Genitourinary Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Boyne+DJ%22">Boyne DJ</searchLink>; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.<br /><searchLink fieldCode="AU" term="%22Warkentin+MT%22">Warkentin MT</searchLink>; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.<br /><searchLink fieldCode="AU" term="%22Brenner+DR%22">Brenner DR</searchLink>; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.<br /><searchLink fieldCode="AU" term="%22Cheung+WY%22">Cheung WY</searchLink>; Arthur JE Child Comprehensive Cancer Centre, University of Calgary, Calgary, Canada; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada.<br /><searchLink fieldCode="AU" term="%22Wells+C%22">Wells C</searchLink>; Arthur JE Child Comprehensive Cancer Centre, University of Calgary, Calgary, Canada.<br /><searchLink fieldCode="AU" term="%22Labaki+C%22">Labaki C</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.<br /><searchLink fieldCode="AU" term="%22McGregor+BA%22">McGregor BA</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.<br /><searchLink fieldCode="AU" term="%22Contreras+LM%22">Contreras LM</searchLink>; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, USA.<br /><searchLink fieldCode="AU" term="%22Pal+SK%22">Pal SK</searchLink>; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, USA.<br /><searchLink fieldCode="AU" term="%22Beuselinck+B%22">Beuselinck B</searchLink>; Department of General Medical Oncology and Laboratory for Experimental Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22McKay+RR%22">McKay RR</searchLink>; Department of Oncology, Moores Cancer Center, University of California San Diego, La Jolla, USA.<br /><searchLink fieldCode="AU" term="%22Szabados+B%22">Szabados B</searchLink>; Barts Cancer Institute, Queen Mary University of London, London, UK.<br /><searchLink fieldCode="AU" term="%22Powles+T%22">Powles T</searchLink>; Barts Cancer Institute, Queen Mary University of London, London, UK.<br /><searchLink fieldCode="AU" term="%22Yuasa+T%22">Yuasa T</searchLink>; Department of Genitourinary Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Ludwig+L%22">Ludwig L</searchLink>; Ipsen Biopharmaceuticals Canada, Inc., Mississauga, Canada.<br /><searchLink fieldCode="AU" term="%22Choueiri+TK%22">Choueiri TK</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA.<br /><searchLink fieldCode="AU" term="%22Heng+DYC%22">Heng DYC</searchLink>; Arthur JE Child Comprehensive Cancer Centre, University of Calgary, Calgary, Canada. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101260955%22">Clinical genitourinary cancer</searchLink> [Clin Genitourin Cancer] 2025 Dec; Vol. 23 (6), pp. 102431. <i>Date of Electronic Publication: </i>2025 Sep 09. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Comparative Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101260955 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1938-0682 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215587673%22">15587673 </searchLink><i>NLM ISO Abbreviation: </i>Clin Genitourin Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41086537 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.clgc.2025.102431 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 102431 Titles: – TitleFull: CABOSEQ 3-Comparison of Cabozantinib versus Sunitinib Following First-Line Nivolumab- Ipilimumab for Metastatic Renal Cell Carcinoma: A Target Trial Emulation Using Real-World Data from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Lemelin A – PersonEntity: Name: NameFull: Maj D – PersonEntity: Name: NameFull: Takemura K – PersonEntity: Name: NameFull: Boyne DJ – PersonEntity: Name: NameFull: Warkentin MT – PersonEntity: Name: NameFull: Brenner DR – PersonEntity: Name: NameFull: Cheung WY – PersonEntity: Name: NameFull: Wells C – PersonEntity: Name: NameFull: Labaki C – PersonEntity: Name: NameFull: McGregor BA – PersonEntity: Name: NameFull: Contreras LM – PersonEntity: Name: NameFull: Pal SK – PersonEntity: Name: NameFull: Beuselinck B – PersonEntity: Name: NameFull: McKay RR – PersonEntity: Name: NameFull: Szabados B – PersonEntity: Name: NameFull: Powles T – PersonEntity: Name: NameFull: Yuasa T – PersonEntity: Name: NameFull: Ludwig L – PersonEntity: Name: NameFull: Choueiri TK – PersonEntity: Name: NameFull: Heng DYC IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 12 Text: 2025 Dec Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1938-0682 Numbering: – Type: volume Value: 23 – Type: issue Value: 6 Titles: – TitleFull: Clinical genitourinary cancer Type: main |
| ResultId | 1 |
